Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

Nerandomilast, a novel anti-fibrotic agent with improved tolerability and a dual antifibrotic/immunomodulatory mechanism, ...

AI's role in early cancer detection and patient outcome improvement is significant, with tools evaluated for utility and ...

A central challenge in relapsed/refractory follicular lymphoma is determining a treatment sequence that maximizes current ...

Guidelines statement on biosimilars was revised to include any appropriate biosimilar for a therapy vs focusing on rituximab.

Nerandomilast's tolerability and dual antifibrotic/immunomodulatory mechanism directly address the critical non-adherence ...

This retrospective analysis is published in Naunyn-Schmiedeberg's Archives of Pharmacology.

Panelists discuss how improving adherence to LDL-lowering therapies is essential for sustained cardiovascular protection.

Panelists discuss how long-term LDL-C exposure heightens cardiovascular risk, making early and sustained lowering crucial.

The ZENITH trial showed sotatercept significantly reduced death, transplant, or hospitalization risk in advanced PAH, leading ...

Value-based care adoption in employer insurance requires replacing fragmented point solutions with unified, at-risk performance contracts that align vendors, providers, and members around total cost ...

Patients with treatment-naïve chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who received pirtobrutinib (Jaypirca; Eli Lilly) monotherapy showed an 80% reduction in progression ...